Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BMYthis companyBristol-Myers Squibb Company	$62.10	15.59×	5.96×	2.28×	9.65×	275.2%	71.1%	28.5%	14.6%	38.2%	15.0%	11.7%	2.55×	2.42×	7.26×	1.26×	4.6%	7	2.7	4	A-
ABBVAbbVie Inc.	$292.30	96.41×	-123.96×	6.63×	26.61×	-55.6%	70.2%	32.8%	6.9%	-129.2%	13.0%	4.4%	-21.12×	3.62×	6.94×	0.67×	2.9%	7	2.9	1	C-
AMGNAmgen Inc.	$463.50	22.84×	20.34×	4.79×	13.11×	92.1%	70.8%	29.1%	21.0%	89.1%	13.2%	4.6%	6.31×	2.69×	3.88×	1.14×	2.9%	8	2.44	3	B+
GILDGilead Sciences, Inc.	$169.50	17.94×	6.73×	5.19×	12.52×	-17.4%	78.8%	39.7%	28.9%	37.5%	20.3%	6.2%	1.1×	1.28×	11.43×	1.55×	2.6%	5	3.97	1	C-
JNJJohnson & Johnson	$279.38	18.82×	6.18×	5.35×	12.97×	7.8%	67.9%	27.2%	28.5%	32.9%	13.7%	3.9%	0.59×	0.69×	26.36×	1.03×	2.5%	7	5.49	3	B+
LLYEli Lilly and Company	$1,396.54	46.58×	36.37×	14.81×	31.57×	-47.2%	83.0%	45.6%	31.7%	77.8%	30.2%	0.9%	1.6×	1.12×	37.34×	1.58×	0.6%	7	9.47	3	B
Peer median	—	22.84×	6.73×	5.35×	13.11×	-17.4%	70.8%	32.8%	28.5%	37.5%	13.7%	4.4%	1.1×	1.28×	11.43×	1.14×	2.6%	7	3.97	3	—